Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 4 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Monoclonal Antibodies Market in Breast Cancer to 2019 Introduction | 9 | 11 |
| Symptoms | 9 | 1 |
| Etiology | 9 | 1 |
| Epidemiology | 10 | 1 |
| Pathophysiology | 10 | 1 |
| Diagnosis | 11 | 1 |
| Prognosis and Disease Staging | 11 | 2 |
| Classification | 13 | 1 |
| Treatment Options | 13 | 1 |
| Surgery and Radiation Therapy | 13 | 1 |
| Chemotherapy | 14 | 1 |
| Hormonal Therapies | 15 | 1 |
| Targeted Therapies | 15 | 1 |
| Resistance to Pharmacological Therapies | 16 | 1 |
| Treatment Guidelines | 17 | 2 |
| Measuring the Effectiveness of Treatment | 19 | 1 |
| Marketed Products | 20 | 11 |
| Herceptin (Trastuzumab) Hoffmann La Roche | 20 | 3 |
| Avastin (Bevacizumab) Hoffmann La Roche | 23 | 2 |
| Kadcyla (Trastuzumab Emtansine) Hoffmann La Roche | 25 | 1 |
| Perjeta (Pertuzumab) Hoffmann La Roche | 26 | 1 |
| Xgeva (denosumab) Amgen | 27 | 1 |
| Heat Map for Marketed Products | 28 | 2 |
| Conclusion | 30 | 1 |
| Pipeline for Breast Cancer Monoclonal Antibody Therapeutics | 31 | 17 |
| Overall Pipeline | 32 | 2 |
| Mechanisms of Action | 34 | 3 |
| Clinical Trials | 37 | 1 |
| Attrition Rate | 37 | 1 |
| Clinical Trial Size | 38 | 2 |
| Duration | 40 | 2 |
| Clinical Trial End-points | 42 | 2 |
| Promising Drug Candidates in the Pipeline | 44 | 1 |
| CDX-011 (glembatumumab vedotin) Celldex Therapeutics | 44 | 1 |
| Metmab (onartuzumab) Hoffman La Roche | 44 | 1 |
| Hu3S193 Recepta Biopharma | 44 | 1 |
| MM-121 Merrimack Pharmaceuticals | 45 | 1 |
| IMC-18F1 (Icrucumab) Eli Lilly | 45 | 1 |
| Rexomun (Ertumaxomab) Fresenius Biotech | 45 | 1 |
| Medi-573 (Dusigitumab) Medimmune | 45 | 1 |
| MK-0646 (Dalotuzumab) Merck and Co | 46 | 1 |
| LY3012217 (Cixutumumab) - Eli Lilly | 46 | 1 |
| Conclusion | 46 | 2 |
| Market Forecast to 2019 | 48 | 12 |
| Global | 48 | 1 |
| Treatment Usage Patterns | 48 | 1 |
| Market Size | 49 | 1 |
| US | 50 | 1 |
| Treatment Usage Patterns | 50 | 1 |
| Market Size | 51 | 1 |
| Canada | 52 | 1 |
| Treatment Usage Patterns | 52 | 1 |
| Market Size | 53 | 1 |
| Europe | 54 | 1 |
| Treatment Usage Patterns | 54 | 1 |
| Annual Cost of Therapy | 55 | 1 |
| Market Size | 56 | 1 |
| Japan | 57 | 1 |
| Treatment Usage Patterns | 57 | 1 |
| Market Size | 58 | 1 |
| Drivers and Barriers | 59 | 1 |
| Drivers | 59 | 1 |
| Recent Approvals of Perjeta and Kadcyla | 59 | 1 |
| Expansion of Perjeta and Kadcyla into the Early-stage Breast Cancer Market | 59 | 1 |
| Rapid Year-on-year Inflation in Specialty Pharmaceuticals in the US | 59 | 1 |
| Weak Erosion of Herceptin Sales by Biosimilars from 2014 | 59 | 1 |
| Barriers | 59 | 1 |
| Relatively Small Phase III Pipeline | 59 | 1 |
| Limited Usage of mAbs in HER-2 Negative Patients | 59 | 1 |
| Black Box Warnings on Currently Marketed Products | 59 | 1 |
| Deals and Strategic Consolidations | 60 | 8 |
| R&D Licensing Agreements | 60 | 3 |
| Key Licensing Deals | 63 | 1 |
| Astellas Pharma Enters into Licensing Agreement with Aveo Pharma for Tivozanib | 63 | 1 |
| Sanofi-Aventis Enters Into Licensing Agreement with Oxford BioMedica | 63 | 1 |
| Taiho Pharma Signs Licensing Agreement with Sanofi-Aventis. | 63 | 1 |
| Takeda Pharma Enters Into Licensing Agreement with Amgen | 63 | 1 |
| Clovis Oncology Enters Into Licensing Agreement with Pfizer For PF-01367338 | 63 | 1 |
| Tesaro Enters Into Licensing Agreement with Merck Sharp &Dohme For Cancer Drug | 64 | 1 |
| Hana Biosciences Enters Into Licensing Agreement with Inex Pharma | 64 | 1 |
| Geron Enters Into Licensing Agreement with Angiochem | 64 | 1 |
| NanoCarrier Enters Into Licensing Agreement with Kowa Company For NC-6300 | 64 | 1 |
| Ariad Pharma Amends its Collaboration Agreement with Merck | 64 | 1 |
| GTx Enters into Licensing Agreement with Merck &Co. | 65 | 1 |
| Co-development Agreements | 65 | 1 |
| Key Deals | 65 | 1 |
| Merck Enters Into Co-Development Agreement With Endocyte For Cancer Drug | 66 | 1 |
| Pfizer Enters Into Research Agreement With BC Cancer Agency And Vancouver Prostate Centre | 67 | 1 |
| Appendix | 68 | 45 |
| References | 68 | 5 |
| References for Heat Map | 73 | 1 |
| All Pipeline Products, by Phase | 74 | 30 |
| Discovery | 74 | 3 |
| Preclinical | 77 | 12 |
| IND/CTA Filed and Phase I | 89 | 6 |
| Phase II | 95 | 7 |
| Phase III and Pre-Registration | 102 | 2 |
| Market Definitions | 104 | 1 |
| Abbreviations | 105 | 1 |
| Tabular Forecast Data | 106 | 3 |
| Global | 106 | 1 |
| US | 106 | 1 |
| Canada | 106 | 1 |
| UK | 107 | 1 |
| France | 107 | 1 |
| Germany | 107 | 1 |
| Italy | 107 | 1 |
| Spain | 108 | 1 |
| Japan | 108 | 1 |
| Research Methodology | 109 | 1 |
| Coverage | 109 | 1 |
| Secondary Research | 109 | 1 |
| Therapeutic Landscape | 110 | 1 |
| Epidemiology-Based Forecasting | 110 | 1 |
| Market Size by Geography | 111 | 1 |
| Geographical Landscape | 112 | 1 |
| Pipeline Analysis | 112 | 1 |
| Competitive Landscape | 112 | 1 |
| Expert Panel Validation | 112 | 1 |
| Contact Us | 112 | 1 |
| Disclaimer | 112 | 1 |